WO2007056217A3 - Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound - Google Patents

Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound Download PDF

Info

Publication number
WO2007056217A3
WO2007056217A3 PCT/US2006/043089 US2006043089W WO2007056217A3 WO 2007056217 A3 WO2007056217 A3 WO 2007056217A3 US 2006043089 W US2006043089 W US 2006043089W WO 2007056217 A3 WO2007056217 A3 WO 2007056217A3
Authority
WO
WIPO (PCT)
Prior art keywords
stent
receptor antagonist
antagonist compound
drug
inhibiting
Prior art date
Application number
PCT/US2006/043089
Other languages
French (fr)
Other versions
WO2007056217A2 (en
Inventor
Jose L Boyer
James G Douglass Iii
Sammy R Shaver
Original Assignee
Inspire Pharmaceuticals Inc
Jose L Boyer
James G Douglass Iii
Sammy R Shaver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/267,941 external-priority patent/US7749981B2/en
Priority claimed from PCT/US2006/017781 external-priority patent/WO2006119507A2/en
Application filed by Inspire Pharmaceuticals Inc, Jose L Boyer, James G Douglass Iii, Sammy R Shaver filed Critical Inspire Pharmaceuticals Inc
Priority to JP2008539087A priority Critical patent/JP2009520510A/en
Priority to EP06827504A priority patent/EP1943261A2/en
Publication of WO2007056217A2 publication Critical patent/WO2007056217A2/en
Publication of WO2007056217A3 publication Critical patent/WO2007056217A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Abstract

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The present invention also provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged blood vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting thrombus formation, inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
PCT/US2006/043089 2005-11-04 2006-11-02 Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound WO2007056217A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008539087A JP2009520510A (en) 2005-11-04 2006-11-02 Drug eluting stent coated with non-nucleotide P2Y12 receptor antagonist compound
EP06827504A EP1943261A2 (en) 2005-11-04 2006-11-02 Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/267,941 US7749981B2 (en) 2003-10-21 2005-11-04 Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US11/267,941 2005-11-04
USPCT/US2006/017781 2006-05-05
PCT/US2006/017781 WO2006119507A2 (en) 2005-05-05 2006-05-05 Non-nucleotide composition and method for inhibiting platelet aggregation

Publications (2)

Publication Number Publication Date
WO2007056217A2 WO2007056217A2 (en) 2007-05-18
WO2007056217A3 true WO2007056217A3 (en) 2007-11-22

Family

ID=38023860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043089 WO2007056217A2 (en) 2005-11-04 2006-11-02 Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound

Country Status (2)

Country Link
EP (1) EP1943261A2 (en)
WO (1) WO2007056217A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
CN111612860B (en) * 2019-02-22 2023-09-15 曹生 VRDS 4D medical image-based Ai identification method and product for embolism

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159388A1 (en) * 2003-10-21 2005-07-21 Plourde Robert Jr. Non-nucleotide compositions and method for inhibiting platelet aggregation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159388A1 (en) * 2003-10-21 2005-07-21 Plourde Robert Jr. Non-nucleotide compositions and method for inhibiting platelet aggregation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GERSHLICK ET AL.: "Inhibition of Restenosis With a Paclitacel-Eluting, Polymer Coronary Stent, The European evaLUation of PacliTaxel Eluting Stent (ELUTES) Trial", CIRCULATION, JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 109, 2004, pages 487 - 493, XP002369061 *

Also Published As

Publication number Publication date
EP1943261A2 (en) 2008-07-16
WO2007056217A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2007056213A3 (en) Drug-eluting stents coated with p2y12 receptor antagonist compound
WO2006036801A3 (en) Drug-delivery endovascular stent and method for treating restenosis
Morton et al. The influence of physical stent parameters upon restenosis
WO2010037144A3 (en) Matrix coated stent
MX2009012766A (en) Absorbable stent having a coating for controlling degradation of the stent and maintaining ph neutrality.
WO2004058100A3 (en) Vascular prosthesis and methods of use
WO2006047289A3 (en) Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
WO2007137298A3 (en) Systems and methods for delivering a rapamycin analog that do not inhibit human coronary artery endothelial cell migration
DE60142290D1 (en) ARTIFICIAL, VASCULAR TRANSPLANT AND PROCESS FOR ITS MANUFACTURE AND ITS USE
WO2007024472A3 (en) USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES
WO2008098252A3 (en) Vascular implants and methods of fabricating the same
MX2010007571A (en) Rapamycin reservoir eluting stent.
US7838021B2 (en) Platforms, particularly prostheses, having biologically active coverings
WO2008051453A3 (en) Drug-delivery endovascular stent and method of use
WO2007139931A3 (en) Bioabsorbable stent with radiopaque coating
WO2004075781A3 (en) Bioactive stents and methods for use thereof
WO2004060318A3 (en) Drug-coated stents and methods of use therefor
Im et al. Current status and future direction of metallic and polymeric materials for advanced vascular stents
WO2008086490A3 (en) Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
WO2004098495A3 (en) Medical devices and methods for inhibiting proliferation of smooth muscle cells
WO2007056217A3 (en) Drug-eluting stents coated with non-nucleotide p2y12 receptor antagonist compound
WO2010042343A3 (en) Combination local delivery using a stent
WO2007137294A3 (en) Dexamethasone-eluting endoprosthesis to promote human coronary artery endothelial cell migration
WO2006105374A3 (en) Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
Ramcharitar et al. Drug-eluting stents, restenosis and revascularization

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006827504

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008539087

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE